<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Neurol</journal-id><journal-id journal-id-type="iso-abbrev">Front Neurol</journal-id><journal-id journal-id-type="publisher-id">Front. Neurol.</journal-id><journal-title-group><journal-title>Frontiers in Neurology</journal-title></journal-title-group><issn pub-type="epub">1664-2295</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401022</article-id><article-id pub-id-type="pmc">PMC12092227</article-id><article-id pub-id-type="doi">10.3389/fneur.2025.1567112</article-id><article-categories><subj-group subj-group-type="heading"><subject>Neurology</subject><subj-group><subject>Mini Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Prognostic value of lymphocyte-to-monocyte ratio in acute ischemic stroke: a systematic review and meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Tian</surname><given-names>Chengli</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Yang</surname><given-names>Yilin</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="fn0001" ref-type="author-notes">
<sup>&#x02020;</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Wan</surname><given-names>Jun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/project-administration/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Ran</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Zhou</surname><given-names>Ke</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Yuanli</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Wenlong</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/investigation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Huijun</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/methodology/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Zhang</surname><given-names>Yu</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xlink:href="https://loop.frontiersin.org/people/1476133/overview"/><role content-type="https://credit.niso.org/contributor-roles/supervision/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Center for Evidence-Based Medicine, Affiliated Hospital of Chengdu University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>Department of Critical Care Medicine, Affiliated Hospital of Chengdu University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by" id="fn0002"><p>Edited by: Haipeng Liu, Coventry University, United Kingdom</p></fn><fn fn-type="edited-by" id="fn0003"><p>Reviewed by: Mona Asghariahmadabad, University of California, San Francisco, United States</p><p>Mohammed Ahmed Akkaif, QingPu Branch of Zhongshan Hospital Affiliated to Fudan University, China</p><p>Wu Zhou, The First Affiliated Hospital of Nanchang University, China</p><p>Muhana Fawwazy Ilyas, Sebelas Maret University, Indonesia</p><p>Dhrumil Shah, Super Metro Specialized Medical Center, Kuwait</p></fn><corresp id="c001">*Correspondence: Yu Zhang, <email>zhangyu1057@cdu.edu.cn</email></corresp><fn fn-type="equal" id="fn0001"><p><sup>&#x02020;</sup>These authors have contributed equally to this work</p></fn></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>16</volume><elocation-id>1567112</elocation-id><history><date date-type="received"><day>25</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>23</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2025 Tian, Yang, Wan, Wang, Zhou, Li, Guo, Li and Zhang.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Tian, Yang, Wan, Wang, Zhou, Li, Guo, Li and Zhang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec id="sec1"><title>Background</title><p>The findings from studies exploring the prognostic relevance of the lymphocyte-to-monocyte ratio (LMR) in individuals with acute ischemic stroke (AIS) have shown variability. We aimed to conduct a meta-analysis to determine the prognostic significance of LMR in this patient population.</p></sec><sec id="sec2"><title>Methods</title><p>We carried out a meta-analysis utilizing information from major databases, including PubMed, Embase, and Web of Science until October 26, 2024. Effect sizes, represented as odds ratios (ORs) along with their corresponding 95% confidence intervals (CI), were synthesized employing a random-effects model in Review Manager Version 5.4. To investigate possible sources of variability, we conducted subgroup analyses. Additionally, publication bias was assessed through the use of a funnel plot. Poor functional outcome at 3 months, as indicated via a modified Rankin Scale score of &#x02265;3, was the main outcome. A moderate to severe stroke, determined by a National Institutes of Health Stroke Scale score of &#x02265;6, was the secondary outcome.</p></sec><sec id="sec3"><title>Results</title><p>Six trials totaling 1,225 individuals were included in our analysis. In AIS patients, we discovered a significant correlation between lower LMR and poorer functional outcome at 3 months, with an OR of 0.63, 95% CI of 0.49 to 0.80, and a <italic>p</italic>-value of 0.0002. Additionally, lower LMR may be associated with developing moderate to severe stroke, with an OR of 0.89 (95% CI: 0.82&#x02013;0.97; <italic>p</italic> =&#x0202f;0.008). In subgroup analyses with an LMR cutoff, a significant association was observed between lower LMR and greater functional impairment in AIS patients, with an odds ratio of 0.74 (95% CI: 0.62&#x02013;0.88; <italic>p</italic> =&#x0202f;0.0005) for LMR&#x0202f;&#x02265;&#x0202f;3 and 0.54 (95% CI: 0.47&#x02013;0.61; <italic>p</italic> &#x0003c;&#x0202f;0.00001) for LMR&#x0202f;&#x0003c;&#x0202f;3. Additionally, when country-stratified, Asian continued to have a significant correlation between worse functional outcome and lower LMR (OR 0.62, 95% CI: 0.50&#x02013;0.77, <italic>p</italic> &#x0003c;&#x0202f;0.0001).</p></sec><sec id="sec4"><title>Conclusion</title><p>This meta-analysis indicated that LMR was a prognostic factor for clinical outcomes in AIS patients.</p></sec></abstract><kwd-group><kwd>lymphocyte-to-monocyte</kwd><kwd>LMR</kwd><kwd>acute ischemic stroke</kwd><kwd>AIS</kwd><kwd>poor functional outcome</kwd><kwd>stroke</kwd><kwd>prognosis</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="2"/><equation-count count="0"/><ref-count count="40"/><page-count count="8"/><word-count count="5484"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Neurological Biomarkers</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec5"><title>Introduction</title><p>A stroke is characterized by its abrupt onset, representing a sudden neurological disruption resulting from the abrupt cessation of cerebral blood flow, which leads to a wide spectrum of neurological deficits (<xref rid="ref1" ref-type="bibr">1</xref>). Strokes are generally classified into two main categories: ischemic and hemorrhagic. Of these, ischemic strokes account for approximately 80% of all cases, with an alarmingly high global incidence of over 13.7 million cases annually, leading to around 5.5 million deaths each year (<xref rid="ref2" ref-type="bibr">2</xref>). Although strokes can affect individuals across all age groups, they primarily affect older adults. However, there has been a concerning rise in the incidence among younger populations (<xref rid="ref2" ref-type="bibr">2</xref>, <xref rid="ref3" ref-type="bibr">3</xref>). Among the different types of stroke, acute ischemic stroke (AIS) is the most common, placing a significant strain on healthcare systems due to its high morbidity and mortality rates, as well as the considerable risks of fatal outcomes and long-term disabling effects (<xref rid="ref4" ref-type="bibr">4</xref>). Thus, identifying reliable prognostic markers is crucial for informed clinical decision-making and personalized patient care.</p><p>Increasing evidence indicates that AIS triggers an inflammatory response (<xref rid="ref5" ref-type="bibr">5&#x02013;7</xref>). There is growing interest in the part inflammatory indicators play in the pathophysiology and outcome of AIS. A cost-effective and easily accessible composite indicator of inflammation in cerebrovascular disease, the lymphocyte-to-monocyte ratio (LMR), which was computed by dividing the lymphocyte count by the monocyte count, integrates the prognostic significance of individual lymphocyte and monocyte levels in relation to AIS (<xref rid="ref8" ref-type="bibr">8</xref>). Previous research has indicated an association between LMR and the severity as well as outcomes of inflammation-related maladies such as myocardial infarction, chronic autoimmune diseases, and peripheral ischemia (<xref rid="ref9" ref-type="bibr">9&#x02013;11</xref>).</p><p>The link between LMR and adverse outcomes in AIS patients continues to be a subject of debate. Although a number of studies have shown a correlation between AIS patients&#x02019; inferior prognosis and lower LMR levels (<xref rid="ref12" ref-type="bibr">12&#x02013;15</xref>), others have failed to establish a significant link between LMR and negative clinical outcomes (<xref rid="ref16" ref-type="bibr">16</xref>). In light of these discrepant results, we carried out this meta-analysis to delve deeper into the relationship between LMR and adverse outcomes among AIS patients.</p></sec><sec sec-type="methods" id="sec6"><title>Methods</title><p>In accordance with the PRISMA statement, this systematic review and meta-analysis has been registered in the PROSPERO database under the registration number CRD42025637708 (<xref rid="ref17" ref-type="bibr">17</xref>).</p><sec id="sec7"><title>Data sources and search strategy</title><p>A thorough systematic review was performed utilizing various databases, such as PubMed, Web of Science, and Embase. Additionally, we hand-searched the bibliographies of all selected studies to locate further pertinent articles. Literature from the inception of these databases to October 26, 2024, was included in the search. The full search strategies are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>.</p></sec><sec id="sec8"><title>Inclusion and exclusion criteria</title><p>The selection process for studies was influenced by these criteria: (1) Patients must be clinically confirmed to have ischemic stroke; (2) The LMR was assessed either upon admission or during the hospital stay for ischemic stroke; (3) Outcome measures included poor functional outcome, or moderate to severe stroke; (4) Participants had to be adults aged 18&#x0202f;years or older. Any studies that met the following criteria were left out of the meta-analysis: (1) They exclusively included patients with hemorrhagic stroke; (2) They were conference abstracts; (3) They were experimental or interventional studies, review articles, preprint studies, or case reports; (4) They lacked sufficient data; (5) They involved non-human subjects.</p></sec><sec id="sec9"><title>Outcomes</title><p>The main result at 3 months was poor functional outcome, which was characterized as a Modified Rankin Scale (MRS) score of three or above. A stroke score of 6 or higher on the National Institutes of Health Stroke Scale (NIHSS) was considered moderate to severe, and this was the secondary outcome.</p></sec><sec id="sec10"><title>Data extraction</title><p>Data extraction was done separately by two researchers, RW and CT, from the chosen studies. They collected specific details, including the lead author&#x02019;s name, publication date, verification methodology, mean participant age, geographical location of the study, total number of participants, gender breakdown, measurement outcomes, the LMR Youden Index, LMR threshold levels, Area Under the Curve (AUC), odds ratio (OR) for adverse functional outcome and moderate to severe stroke cases, and their associated 95% confidence interval (CI). When studies provided both univariate and multivariate regression analyses, the latter was utilized to derive the cumulative OR. To ensure data accuracy, a third researcher (YL) conducted an independent verification. Within the collaboration, disagreements between the original reviewers were settled via cooperative discussion.</p></sec><sec id="sec11"><title>Assessment of quality</title><p>Cohort study quality was rated by two reviewers (RW and CT) adopting the Newcastle&#x02013;Ottawa Quality Assessment Scale (NOS), with scores ranging from 0 to 9. Studies scoring 7 or higher were deemed high quality (<xref rid="ref18" ref-type="bibr">18</xref>). Each study was independently evaluated by the reviewers in line with the designated scale. Any differences were reconciled by means of discussions with an additional author (YL).</p></sec><sec id="sec12"><title>Statistical analysis</title><p>RevMan 5.4.1 from The Cochrane Collaboration was used for statistical analysis. For categorical data, the OR and associating 95% CI were determined. The degree of variability was quantified by using the I<sup>2</sup> statistic to calculate the percentage of variability attributable to study variability, with a <italic>p</italic>-value of less than 0.05 being deemed statistically significant. Because of the diversity shown in the trials, a random-effects model was used to synthesize the findings. To determine the degree of heterogeneity, I<sup>2</sup> statistics and Chi-square tests were applied, with a study considered significantly heterogeneous when <italic>p</italic> &#x0003c;&#x0202f;0.05 and I<sup>2</sup> exceeded 50%. Forest plots were created to visualize the estimated effect sizes along with their 95% CI. By employing these rigorous statistical techniques, our goal was to deliver a thorough and comprehensive analysis of the data. We visually inspected the funnel plot to qualitatively assess the potential effects of small studies. Additionally, we performed a sensitivity analysis by removing studies one at a time in order to examine how each study affected the overall impact size. Moreover, the egger test (<xref rid="ref19" ref-type="bibr">19</xref>) was applied for quantitative analysis, facilitating a meticulous assessment of any bias that might arise from small-study effects.</p></sec><sec id="sec13"><title>Subgroup analysis</title><p>We conducted a subgroup analysis of the primary outcome according to age, country, LMR cutoff values, and the specific characteristics of the study subjects.</p></sec></sec><sec sec-type="results" id="sec14"><title>Results</title><sec id="sec15"><title>Study inclusion</title><p><xref rid="fig1" ref-type="fig">Figure 1</xref> illustrates the flowchart detailing the research design. A comprehensive literature search, employing specific keywords, initially identified 636 articles. After eliminating duplicates, 191 studies were excluded. Subsequently, 423 irrelevant articles were excluded. Among the remaining 22, 5 were excluded for inaccessible full-texts. Following a thorough review, 11 additional articles were disqualified for not fulfilling the predetermined inclusion requirements. In the end, the meta-analysis had six publications (<xref rid="ref12" ref-type="bibr">12&#x02013;15</xref>, <xref rid="ref20" ref-type="bibr">20</xref>, <xref rid="ref21" ref-type="bibr">21</xref>).</p><fig position="float" id="fig1"><label>Figure 1</label><caption><p>PRISMA study flow diagram.</p></caption><graphic xlink:href="fneur-16-1567112-g001" position="float"/></fig></sec><sec id="sec16"><title>Summary of studies</title><p><xref rid="tab1" ref-type="table">Table 1</xref> offers a comprehensive summary of details of the included research. In total, 1,225 individuals diagnosed with AIS were documented across six retrospective studies. All included studies adjusted for potential confounders through multivariate models. The initial studies predominantly focused on populations from China, the UK (<xref rid="ref21" ref-type="bibr">21</xref>), and Trnava, Slovakia (<xref rid="ref12" ref-type="bibr">12</xref>). The primary source of data was the Department of Neurology at Chengde Medical University&#x02019;s affiliated hospital (<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref15" ref-type="bibr">15</xref>). The analysis revealed a higher prevalence of male patients with AIS, with the mean age exceeding 50&#x0202f;years. Stroke diagnoses were confirmed through clinical evaluations, imaging studies, and comprehensive diagnostic assessments.</p><table-wrap position="float" id="tab1"><label>Table 1</label><caption><p>Basic statistical characteristics of included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Studies</th><th align="center" valign="top" rowspan="1" colspan="1">Country</th><th align="center" valign="top" rowspan="1" colspan="1">Age, year</th><th align="center" valign="top" rowspan="1" colspan="1"><italic>N</italic> (F/M)</th><th align="center" valign="top" rowspan="1" colspan="1">Confirmed method</th><th align="center" valign="top" rowspan="1" colspan="1">AUC</th><th align="center" valign="top" rowspan="1" colspan="1">cutoff value</th><th align="center" valign="top" rowspan="1" colspan="1">Youden index</th><th align="center" valign="top" rowspan="1" colspan="1">Outcome measures</th><th align="center" valign="top" rowspan="1" colspan="1">NOS</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Guan et al., 2023 (<xref rid="ref13" ref-type="bibr">13</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">71.0 (63.0&#x02013;81.0)</td><td align="center" valign="top" rowspan="1" colspan="1">101 (37/64)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">0.789</td><td align="center" valign="top" rowspan="1" colspan="1">1.92</td><td align="center" valign="top" rowspan="1" colspan="1">0.531</td><td align="center" valign="top" rowspan="1" colspan="1">MRS</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ren et al., 2017 (<xref rid="ref14" ref-type="bibr">14</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">61.0 (55.0&#x02013;74.0)</td><td align="center" valign="top" rowspan="1" colspan="1">512 (198/314)</td><td align="center" valign="top" rowspan="1" colspan="1">MRI</td><td align="center" valign="top" rowspan="1" colspan="1">0.826</td><td align="center" valign="top" rowspan="1" colspan="1">2.99</td><td align="center" valign="top" rowspan="1" colspan="1">0.559</td><td align="center" valign="top" rowspan="1" colspan="1">MRS NIHSS</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lux et al., 2020 (<xref rid="ref21" ref-type="bibr">21</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">UK</td><td align="center" valign="top" rowspan="1" colspan="1">66.4 (49.7&#x02013;83.1)</td><td align="center" valign="top" rowspan="1" colspan="1">121 (58/63)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">2.00</td><td align="center" valign="top" rowspan="1" colspan="1">0.300</td><td align="center" valign="top" rowspan="1" colspan="1">MRS</td><td align="center" valign="top" rowspan="1" colspan="1">6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Pin&#x0010d;&#x000e1;kov&#x000e1; et al., 2022 (<xref rid="ref12" ref-type="bibr">12</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">Trnava, Slovakia</td><td align="center" valign="top" rowspan="1" colspan="1">72.0 (69.0&#x02013;81.0)</td><td align="center" valign="top" rowspan="1" colspan="1">179 (90/89)</td><td align="center" valign="top" rowspan="1" colspan="1">CTA<break/>MRA<break/>DSA</td><td align="center" valign="top" rowspan="1" colspan="1">0.616</td><td align="center" valign="top" rowspan="1" colspan="1">3.27</td><td align="center" valign="top" rowspan="1" colspan="1">0.280</td><td align="center" valign="top" rowspan="1" colspan="1">MRS</td><td align="center" valign="top" rowspan="1" colspan="1">7</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ren et al., 2017 (<xref rid="ref15" ref-type="bibr">15</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">56.0 (52.0&#x02013;69.0)</td><td align="center" valign="top" rowspan="1" colspan="1">108 (32/76)</td><td align="center" valign="top" rowspan="1" colspan="1">MRI<break/>CT</td><td align="center" valign="top" rowspan="1" colspan="1">0.767</td><td align="center" valign="top" rowspan="1" colspan="1">3.48</td><td align="center" valign="top" rowspan="1" colspan="1">0.521</td><td align="center" valign="top" rowspan="1" colspan="1">MRS NIHSS</td><td align="center" valign="top" rowspan="1" colspan="1">9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Zhang et al., 2024 (<xref rid="ref20" ref-type="bibr">20</xref>)</td><td align="center" valign="top" rowspan="1" colspan="1">China</td><td align="center" valign="top" rowspan="1" colspan="1">69.1 (56.8&#x02013;81.4)</td><td align="center" valign="top" rowspan="1" colspan="1">204 (73/131)</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">MRS</td><td align="center" valign="top" rowspan="1" colspan="1">8</td></tr></tbody></table><table-wrap-foot><p>CT, computed tomography; MRI, magnetic resonance imaging; N (F/M), number of patients (female/male); AUC, area under the curve; CTA, computed tomography angiography; MRA, magnetic resonance angiography; DSA, digital subtraction angiography; MRS, modified Rankin Scale; NIHSS, the National Institute of Health Stroke Scale; NOS, Newcastle-Ottawa Scale.</p></table-wrap-foot></table-wrap></sec><sec id="sec17"><title>Overall assessment of evidence quality</title><p>The evaluation of the cohort investigations employing the NOS This led to scores of 9 in two studies (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref20" ref-type="bibr">20</xref>), 8 in one study (<xref rid="ref12" ref-type="bibr">12</xref>), 7 in two studies (<xref rid="ref14" ref-type="bibr">14</xref>, <xref rid="ref15" ref-type="bibr">15</xref>), and 6 in another one (<xref rid="ref21" ref-type="bibr">21</xref>). The differences in scores primarily depended on the extent to which confounders were controlled and the rigor of participant follow-up (<xref rid="SM2" ref-type="supplementary-material">Supplementary Table S2</xref>).</p></sec><sec id="sec18"><title>Overall efficacy</title><p>The incidence of poor functional outcome in AIS patients at 3 months was the main outcome that was measured. This was determined by combining effect sizes from six studies, which collectively included 1,225 participants. The pooled OR for these studies was 0.63 (95% CI: 0.49&#x02013;0.80, <italic>p</italic> =&#x0202f;0.0002), as shown in <xref rid="fig2" ref-type="fig">Figure 2</xref>. According to this finding, AIS patients who have a lower LMR are more likely to experience poorer functional results at 3 months. Notably, there was considerable variation among the trials (I<sup>2</sup> =&#x0202f;77%, <italic>p</italic> =&#x0202f;0.0005).</p><fig position="float" id="fig2"><label>Figure 2</label><caption><p>Forest plot of the association between lymphocyte-to-monocyte ratio and poor functional outcome at 3&#x0202f;months.</p></caption><graphic xlink:href="fneur-16-1567112-g002" position="float"/></fig><p>The secondary outcome was the occurrence of moderate to severe stroke in patients with AIS. Two studies evaluated moderate to severe stroke as an outcome, resulting in a pooled OR of 0.89 (95% CI: 0.82&#x02013;0.97, <italic>p</italic> =&#x0202f;0.008), according to <xref rid="fig3" ref-type="fig">Figure 3</xref>. There was no difference between the investigations (I<sup>2</sup> =&#x0202f;0, <italic>p</italic> =&#x0202f;0.85).</p><fig position="float" id="fig3"><label>Figure 3</label><caption><p>Forest plot of the association between lymphocyte-to-monocyte ratio and moderate to severe stroke.</p></caption><graphic xlink:href="fneur-16-1567112-g003" position="float"/></fig></sec><sec id="sec19"><title>Subgroup analyses</title><p>We performed a subgroup analysis focusing on studies that used poor functional outcome at 3 months as the primary outcome measure. The results, shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S1</xref>, reveal that the aggregated OR for poor functional outcome was 0.62 (95% CI: 0.50&#x02013;0.77; <italic>p</italic> &#x0003c;&#x0202f;0.0001) for studies conducted in Asian, and 0.30 (95% CI: 0.04&#x02013;2.30; <italic>p</italic> =&#x0202f;0.24) for studies conducted in non-Asian. Among all included studies, two reported a LMR cutoff value &#x02265; 3, yielding a pooled OR for poor functional outcome of 0.74 (95% CI: 0.62&#x02013;0.88; <italic>p</italic> =&#x0202f;0.0005). In contrast, the LMR cutoff values reported in the other three studies ranged between 0 and 3, resulting in a combined OR of 0.50 (95% CI: 0.35&#x02013;0.70; <italic>p</italic> &#x0003c;&#x0202f;0.0001). According to sensitivity analysis, the Lux et al. (<xref rid="ref21" ref-type="bibr">21</xref>) study affected the overall findings, most likely as a function of the timing of the LMR measurements. In their study, LMR was measured 24&#x0202f;h after mechanical thrombectomy (MT), whereas other included studies measured LMR at admission or during the initial hospital stay (<xref rid="ref13" ref-type="bibr">13</xref>, <xref rid="ref14" ref-type="bibr">14</xref>). This variability in timing of LMR measurement may have contributed to the observed heterogeneity. Excluding this study resulted in a pooled OR of 0.54 (95% CI: 0.47&#x02013;0.61, <italic>p</italic> &#x0003c;&#x0202f;0.00001), based on <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S2</xref>. One study did not specify an LMR cutoff value. Furthermore, a subgroup analysis based on age (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3</xref>) demonstrated that the pooled OR for poor functional outcome at 3 months was 0.65 (95% CI: 0.46&#x02013;0.93; <italic>p</italic> =&#x0202f;0.02) for patients aged 65 and older, and 0.57 (95% CI: 0.43&#x02013;0.75; <italic>p</italic> &#x0003c;&#x0202f;0.0001) for those younger than 65. The analysis also included two studies focusing on AIS patients who underwent MT, resulting in an OR of 0.30 (95% CI: 0.04&#x02013;2.30; <italic>p</italic> =&#x0202f;0.24). Additionally, two trials including AIS patients evaluated the impact of recombinant tissue plasminogen activator (rt-PA), resulting in an OR of 0.77 (95% CI: 0.57&#x02013;1.03; <italic>p</italic> =&#x0202f;0.08). Another study focused on AIS patients who received endovascular therapy (EVT), yielding a pooled OR of 0.61 (95% CI: 0.48&#x02013;0.76). Lastly, one study addressed AIS patients more generally, reporting a pooled OR of 0.51 (95% CI: 0.44&#x02013;0.59), as illustrated in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4</xref>. All pooled results are summarized in <xref rid="tab2" ref-type="table">Table 2</xref>.</p><table-wrap position="float" id="tab2"><label>Table 2</label><caption><p>Subgroup analysis results of poor functional outcome at 3&#x0202f;months.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top" rowspan="1" colspan="1">Groups</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>N</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">Model</th><th align="center" valign="top" rowspan="1" colspan="1">Pooled OR (95%CI)</th><th align="center" valign="top" rowspan="1" colspan="1">
<italic>p</italic>
</th><th align="center" valign="top" rowspan="1" colspan="1">Heterogeneity (P, I2)</th><th align="center" valign="top" rowspan="1" colspan="1">Conclusion</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Total</td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 (0.49,0.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0002</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005,77%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.62 (0.50, 0.77)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.04,63%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">No-Asian</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30 (0.04, 2.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002,89%</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age &#x02265; 65</td><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.65 (0.46, 0.93)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02</td><td align="center" valign="middle" rowspan="1" colspan="1">0.006,76%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Age &#x0003c; 65</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.57 (0.43, 0.75)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11,61%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LMR&#x0202f;&#x02265;&#x0202f;3</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Fixed</td><td align="center" valign="middle" rowspan="1" colspan="1">0.74 (0.62, 0.88)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.0005</td><td align="center" valign="middle" rowspan="1" colspan="1">0.58,0%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LMR&#x0202f;&#x0003c;&#x0202f;3</td><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.50 (0.35, 0.70)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.0001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.02,76%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LMR&#x0202f;&#x0003c;&#x0202f;3, Lux 2020 trials excluded</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Fixed</td><td align="center" valign="middle" rowspan="1" colspan="1">0.54 (0.47, 0.61)</td><td align="center" valign="middle" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.00001</td><td align="center" valign="middle" rowspan="1" colspan="1">0.19,41%</td><td align="center" valign="middle" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIS patients after MT</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Random</td><td align="center" valign="middle" rowspan="1" colspan="1">0.30 (0.04, 2.30)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.24</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002,89%</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AIS patients after rt-PA</td><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">Fixed</td><td align="center" valign="middle" rowspan="1" colspan="1">0.76 (0.58, 1.00)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.05</td><td align="center" valign="middle" rowspan="1" colspan="1">0.28,14%</td><td align="center" valign="middle" rowspan="1" colspan="1">Negative</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIS patients after EVT</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Random</td><td align="center" valign="top" rowspan="1" colspan="1">0.61 (0.48, 0.76)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.0001</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">AIS patients</td><td align="center" valign="top" rowspan="1" colspan="1">1</td><td align="center" valign="top" rowspan="1" colspan="1">Random</td><td align="center" valign="top" rowspan="1" colspan="1">0.51 (0.44, 0.59)</td><td align="center" valign="top" rowspan="1" colspan="1"><italic>p</italic> &#x0003c;&#x0202f;0.00001</td><td align="center" valign="top" rowspan="1" colspan="1">-</td><td align="center" valign="top" rowspan="1" colspan="1">Positive</td></tr></tbody></table><table-wrap-foot><p>
<italic>N, number; CI, confidence interval; OR, odds ratio; LMR, lymphocyte-to-monocyte ratio; MT, mechanical thrombectomy; rt-PA, recombinant tissue plasminogen activator; EVT, endovascular treatment.</italic>
</p></table-wrap-foot></table-wrap></sec><sec id="sec20"><title>Sensitivity analysis and publication bias</title><p>One study at a time was eliminated in order to do a sensitivity analysis. The findings of this analysis are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S3</xref>. The sensitivity analysis indicated that the pooled OR for studies reporting poor functional outcome remained stable, with no significant changes observed after the exclusion of any individual study. Additionally, publication bias was evaluated and is presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figures S5</xref>, <xref rid="SM1" ref-type="supplementary-material">S6</xref>. No substantial bias was identified in the meta-analysis.</p></sec></sec><sec sec-type="discussion" id="sec21"><title>Discussion</title><p>To our knowledge, this meta-analysis represents the pioneering investigation in its field that, by implementing rigorous search protocols, established the absence of prior systematic reviews&#x02014;even those tangentially examining inflammatory biomarkers in acute ischemic stroke, including information from six distinct investigations. Our findings suggest that a lower LMR is associated with worse functional outcome at 3 months and may also indicate a higher likelihood of moderate to severe stroke occurrence.</p><p>The relationship between the LMR and AIS has not yet been the subject of any meta-analysis. Our study uniquely focuses on this relationship within the AIS population, proving that LMR may indicate a useful predictor of poor functional outcome in patients with AIS. Furthermore, our findings indicate that reduced LMR levels are associated with a higher risk of progressing to moderate to severe stroke. Additionally, the place of origin, research parameters, and cutoff values were among the factors that affected the association between LMR and AIS, according to our analysis.</p><p>The LMR is a marker that reflects the proportion of lymphocytes relative to monocytes in the peripheral circulation. This ratio serves as an inflammatory biomarker and has been associated with inflammation, disease activity, and prognosis in various clinical conditions (<xref rid="ref22" ref-type="bibr">22</xref>). In different clinical settings, variations in LMR can aid physicians in assessing a patient&#x02019;s immune response. For example, in patients with cancer, higher LMR levels are often associated with more favorable prognosis, as elevated LMR may indicate a more robust immune response (<xref rid="ref23" ref-type="bibr">23</xref>). On the other hand, a decreased LMR may signify heightened inflammation or immune suppression, factors commonly associated with worse treatment outcomes and lower survival rates. Additionally, LMR has been used to assess the risk of cardiovascular diseases, and evaluate the activity of other chronic inflammatory conditions (<xref rid="ref22" ref-type="bibr">22</xref>, <xref rid="ref24" ref-type="bibr">24</xref>, <xref rid="ref25" ref-type="bibr">25</xref>). Clinical observation indicated that lymphocyte levels demonstrated neuroprotective capacities, which may facilitate the restoration of compromised neural functions (<xref rid="ref26" ref-type="bibr">26</xref>). In contrast, monocytes, recognized as critical immune modulators that amplify post-stroke inflammatory cascades, demonstrate the capacity to migrate into ischemic regions and exacerbate cerebral injury (<xref rid="ref27" ref-type="bibr">27</xref>). Clinical investigations have further established that elevated monocyte concentrations correlate with unfavorable therapeutic outcomes in acute ischemic stroke, as supported by a study (<xref rid="ref28" ref-type="bibr">28</xref>). Consequently, decreased LMR levels may serve as a valuable prognostic indicator for AIS outcomes. Clinicians can gain important information about a patient&#x02019;s general health and the course of their sickness by tracking blood indicators like LMR.</p><p>Our analysis suggests that the LMR is a valuable prognostic marker for predicting poor functional outcome 3 months following AIS. It is crucial to understand that a variety of factors, such as comprehensive rehabilitation efforts, the initial severity of the stroke, and the specific emergency interventions administered, affect these results (<xref rid="ref29" ref-type="bibr">29&#x02013;34</xref>). Additionally, several potential confounding factors warrant consideration. For instance, stroke subtype may differentially influence inflammatory responses and subsequent LMR dynamics (<xref rid="ref35" ref-type="bibr">35</xref>). Baseline comorbidities such as diabetes, hypertension, or chronic inflammatory conditions may modulate both lymphocyte and monocyte counts, thereby confounding the LMR-outcome association (<xref rid="ref36" ref-type="bibr">36</xref>, <xref rid="ref37" ref-type="bibr">37</xref>). Pre-stroke functional status, as assessed by metrics like the MRS prior to the index event, might independently predict recovery trajectories and interact with LMR&#x02019;s prognostic utility (<xref rid="ref38" ref-type="bibr">38</xref>). Furthermore, variations in acute therapies may alter the inflammatory milieu and LMR values, necessitating careful adjustment in future studies (<xref rid="ref39" ref-type="bibr">39</xref>, <xref rid="ref40" ref-type="bibr">40</xref>). Our findings indicate that a lower LMR cutoff value is more predictive of poorer functional outcome at 3 months in AIS patients. Consistent with this, Guan et al. (<xref rid="ref13" ref-type="bibr">13</xref>) showed that a threshold value of 1.92 was found for the independent correlation between a lower LMR and a higher likelihood of poor functional outcome 3 months after a stroke. Similarly, Lux et al. (<xref rid="ref21" ref-type="bibr">21</xref>) reported that a lower LMR cutoff of 2, with a sensitivity of 80% and specificity of 50%, was also associated with AIS patients having a higher chance of experiencing poor functional outcome at 3 months.</p><p>We conducted the subgroup analyses to identify and minimize factors contributing to heterogeneity. In the Asian group, a lower LMR was associated with worse functional outcomes, whereas this relationship was non-significant in the non-Asian group, potentially due to the smaller sample size and increased risk of Type II error. Biological factors such as genetic differences in inflammation and platelet biology, as well as healthcare system and environmental variations, may also influence these findings. Furthermore, testing of different LMR cutoff values revealed that a cutoff of 3 was most predictive of disease progression and prognosis, with lower cutoff values showing stronger associations. LMR demonstrated greater prognostic utility in younger patients, likely due to preserved immune function, while aging, comorbidities, and polypharmacy in the elderly may diminish its predictive value. Through the subgroup analyses, we examined potential sources of heterogeneity and identified factors such as country of origin, age and LMR cutoff value as plausible contributors.</p><p>Despite our adherence to rigorous standards in study selection, data extraction, and quality assessment, several limitations were inherent in our study. A key limitation of this meta-analysis is the retrospective design of most included studies, which may introduce selection bias and confounding factors, potentially affecting the reliability of the pooled effect estimates. First, subgroup analyses, such as those based on ethnicity and LMR cutoff values, should be interpreted with caution due to limited study numbers, particularly in the non-Asian subgroup, which had only two studies, limiting statistical power. Second, variations in LMR cutoff values and measurement timing across studies contribute to heterogeneity, underscoring the need for standardized protocols in future research to improve comparability and reduce variability. Moreover, as most of the studies in this analysis were based in Asia, particularly China, caution was needed when generalizing these findings. Additionally, the random-effects model highlighted significant variability across studies, suggesting potential publication bias.</p><p>The use of the LMR as a biomarker in AIS patients offers significant clinical advantages. LMR can help identify patients at higher risk for moderate to severe stroke and poor functional outcomes, enabling personalized management strategies. It also aids in treatment decisions, guiding clinicians to consider more aggressive interventions for poor prognostic cases. Integration of LMR with point-of-care testing devices, particularly in emergency settings, facilitates real-time risk assessment and decision-making during the critical golden hour. Additionally, educating patients on the implications of LMR can improve patient engagement and treatment adherence, ultimately enhancing outcomes and recovery.</p></sec><sec sec-type="conclusions" id="sec22"><title>Conclusion</title><p>Three months after an acute ischemic stroke, our study unequivocally showed a substantial correlation between the LMR and poor functional outcome. Specifically, lower LMR was associated with poorer functional outcome and a higher risk of developing moderate to severe stroke. These findings indicate that LMR may be a valuable prognostic tool for guiding management and identifying high-risk acute ischemic stroke patients who require closer post-treatment monitoring.</p></sec></body><back><sec sec-type="author-contributions" id="sec24"><title>Author contributions</title><p>CT: Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft. YY: Writing &#x02013; review &#x00026; editing. JW: Project administration, Writing &#x02013; original draft. RW: Data curation, Formal analysis, Methodology, Writing &#x02013; original draft. KZ: Data curation, Investigation, Methodology, Writing &#x02013; original draft. YL: Data curation, Formal analysis, Writing &#x02013; original draft. WG: Investigation, Writing &#x02013; original draft. HL: Methodology, Writing &#x02013; original draft. YZ: Supervision, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="sec26"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="sec27"><title>Generative AI statement</title><p>The authors declare that no Gen AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="sec28"><title>Publisher&#x02019;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><sec sec-type="supplementary-material" id="sec29"><title>Supplementary material</title><p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fneur.2025.1567112/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fneur.2025.1567112/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data"><media xlink:href="Table_1.docx"/></supplementary-material><supplementary-material id="SM2" position="float" content-type="local-data"><media xlink:href="Table_2.docx"/></supplementary-material></sec><ref-list><title>References</title><ref id="ref1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacco</surname><given-names>RL</given-names></name><name><surname>Kasner</surname><given-names>SE</given-names></name><name><surname>Broderick</surname><given-names>JP</given-names></name><name><surname>Caplan</surname><given-names>LR</given-names></name><name><surname>Connors</surname><given-names>JJ</given-names></name><name><surname>Culebras</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. (<year>2013</year>) <volume>44</volume>:<fpage>2064</fpage>&#x02013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STR.0b013e318296aeca</pub-id>, PMID: <pub-id pub-id-type="pmid">23652265</pub-id>
</mixed-citation></ref><ref id="ref2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feske</surname><given-names>SK</given-names></name></person-group>. <article-title>Ischemic Stroke</article-title>. <source>Am J Med</source>. (<year>2021</year>) <volume>134</volume>:<fpage>1457</fpage>&#x02013;<lpage>64</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.amjmed.2021.07.027</pub-id>, PMID: <pub-id pub-id-type="pmid">34454905</pub-id>
</mixed-citation></ref><ref id="ref3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab id="coll1">NCD Countdown 2030 Collaborators</collab></person-group>. <article-title>NCD countdown 2030: worldwide trends in non-communicable disease mortality and progress towards sustainable development goal target 3.4</article-title>. <source>Lancet</source>. (<year>2018</year>) <volume>392</volume>:<fpage>1072</fpage>&#x02013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31992-5</pub-id><pub-id pub-id-type="pmid">30264707</pub-id>
</mixed-citation></ref><ref id="ref4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ospel</surname><given-names>JM</given-names></name><name><surname>Holodinsky</surname><given-names>JK</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name></person-group>. <article-title>Management of Acute Ischemic Stroke due to large-vessel occlusion: JACC focus seminar</article-title>. <source>J Am Coll Cardiol</source>. (<year>2020</year>) <volume>75</volume>:<fpage>1832</fpage>&#x02013;<lpage>43</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2019.10.034</pub-id><pub-id pub-id-type="pmid">32299595</pub-id>
</mixed-citation></ref><ref id="ref5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maida</surname><given-names>CD</given-names></name><name><surname>Norrito</surname><given-names>RL</given-names></name><name><surname>Daidone</surname><given-names>M</given-names></name><name><surname>Tuttolomondo</surname><given-names>A</given-names></name><name><surname>Pinto</surname><given-names>A</given-names></name></person-group>. <article-title>Neuroinflammatory mechanisms in ischemic stroke: focus on Cardioembolic stroke, background, and therapeutic approaches</article-title>. <source>Int J Mol Sci</source>. (<year>2020</year>) <volume>21</volume>:<fpage>454</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijms21186454</pub-id>, PMID: <pub-id pub-id-type="pmid">31936829</pub-id>
</mixed-citation></ref><ref id="ref6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endres</surname><given-names>M</given-names></name><name><surname>Moro</surname><given-names>MA</given-names></name><name><surname>Nolte</surname><given-names>CH</given-names></name><name><surname>Dames</surname><given-names>C</given-names></name><name><surname>Buckwalter</surname><given-names>MS</given-names></name><name><surname>Meisel</surname><given-names>A</given-names></name></person-group>. <article-title>Immune pathways in etiology, acute phase, and chronic sequelae of ischemic stroke</article-title>. <source>Circ Res</source>. (<year>2022</year>) <volume>130</volume>:<fpage>1167</fpage>&#x02013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.121.319994</pub-id>, PMID: <pub-id pub-id-type="pmid">35420915</pub-id>
</mixed-citation></ref><ref id="ref7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alsbrook</surname><given-names>DL</given-names></name><name><surname>Di Napoli</surname><given-names>M</given-names></name><name><surname>Bhatia</surname><given-names>K</given-names></name><name><surname>Biller</surname><given-names>J</given-names></name><name><surname>Andalib</surname><given-names>S</given-names></name><name><surname>Hinduja</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Neuroinflammation in acute ischemic and hemorrhagic stroke</article-title>. <source>Curr Neurol Neurosci Rep</source>. (<year>2023</year>) <volume>23</volume>:<fpage>407</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s11910-023-01282-2</pub-id>, PMID: <pub-id pub-id-type="pmid">37395873</pub-id>
</mixed-citation></ref><ref id="ref8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name></person-group>. <article-title>Predictive values of systemic inflammatory responses index in early neurological deterioration in patients with acute ischemic stroke</article-title>. <source>J Integr Neurosci</source>. (<year>2022</year>) <volume>21</volume>:<fpage>94</fpage>. doi: <pub-id pub-id-type="doi">10.31083/j.jin2103094</pub-id>, PMID: <pub-id pub-id-type="pmid">35633175</pub-id>
</mixed-citation></ref><ref id="ref9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>ES</given-names></name><name><surname>You</surname><given-names>Z</given-names></name><name><surname>Nowak</surname><given-names>KL</given-names></name><name><surname>Jovanovich</surname><given-names>AJ</given-names></name></person-group>. <article-title>Association of Monocyte Count and Monocyte/lymphocyte ratio with the risk of cardiovascular outcomes in patients with CKD</article-title>. <source>Kidney360</source>. (<year>2022</year>) <volume>3</volume>:<fpage>657</fpage>&#x02013;<lpage>65</lpage>. doi: <pub-id pub-id-type="doi">10.34067/KID.0007922021</pub-id>, PMID: <pub-id pub-id-type="pmid">35721602</pub-id>
</mixed-citation></ref><ref id="ref10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Demirba&#x0015f;</surname><given-names>A</given-names></name><name><surname>Elmas</surname><given-names>&#x000d6;F</given-names></name><name><surname>Atasoy</surname><given-names>M</given-names></name><name><surname>T&#x000fc;rsen</surname><given-names>&#x000dc;</given-names></name><name><surname>Lotti</surname><given-names>T</given-names></name></person-group>. <article-title>Can monocyte to HDL cholesterol ratio and monocyte to lymphocyte ratio be markers for inflammation and oxidative stress in patients with vitiligo? A preliminary study</article-title>. <source>Arch Dermatol Res</source>. (<year>2021</year>) <volume>313</volume>:<fpage>491</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00403-020-02129-3</pub-id>, PMID: <pub-id pub-id-type="pmid">32816078</pub-id>
</mixed-citation></ref><ref id="ref11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Xiong</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Song</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Neutrophil percentage-to-albumin ratio and monocyte-to-lymphocyte ratio as predictors of free-wall rupture in patients with acute myocardial infarction</article-title>. <source>J Clin Lab Anal</source>. (<year>2022</year>) <volume>36</volume>:<fpage>e24136</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jcla.24136</pub-id>, PMID: <pub-id pub-id-type="pmid">34820903</pub-id>
</mixed-citation></ref><ref id="ref12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pin&#x0010d;&#x000e1;kov&#x000e1;</surname><given-names>K</given-names></name><name><surname>Krastev</surname><given-names>G</given-names></name><name><surname>Haring</surname><given-names>J</given-names></name><name><surname>Mako</surname><given-names>M</given-names></name><name><surname>Mikul&#x000e1;&#x00161;kov&#x000e1;</surname><given-names>V</given-names></name><name><surname>Bo&#x00161;&#x000e1;k</surname><given-names>V</given-names></name></person-group>. <article-title>Low lymphocyte-to-monocyte ratio as a possible predictor of an Unfavourable clinical outcome in patients with acute ischemic stroke after mechanical Thrombectomy</article-title>. <source>Stroke Res Treatment</source>. (<year>2022</year>) <volume>2022</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1155/2022/9243080</pub-id>, PMID: <pub-id pub-id-type="pmid">36536620</pub-id>
</mixed-citation></ref><ref id="ref13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group>. <article-title>Lymphocyte to monocyte ratio is independently associated with futile recanalization in acute ischemic stroke after endovascular therapy</article-title>. <source>Neuropsychiatr Dis Treat</source>. (<year>2023</year>) <volume>19</volume>:<fpage>2585</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.2147/NDT.S434225</pub-id>, PMID: <pub-id pub-id-type="pmid">38046831</pub-id>
</mixed-citation></ref><ref id="ref14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group>. <article-title>Lymphocyte-to-monocyte ratio: a novel predictor of the prognosis of acute ischemic stroke</article-title>. <source>J Stroke Cerebrovasc Dis</source>. (<year>2017</year>) <volume>26</volume>:<fpage>2595</fpage>&#x02013;<lpage>602</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jstrokecerebrovasdis.2017.06.019</pub-id>, PMID: <pub-id pub-id-type="pmid">28847530</pub-id>
</mixed-citation></ref><ref id="ref15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group>. <article-title>Decreased lymphocyte-to-monocyte ratio predicts poor prognosis of acute ischemic stroke treated with thrombolysis</article-title>. <source>Med Sci Monit</source>. (<year>2017</year>) <volume>23</volume>:<fpage>5826</fpage>&#x02013;<lpage>33</lpage>. doi: <pub-id pub-id-type="doi">10.12659/MSM.907919</pub-id>, PMID: <pub-id pub-id-type="pmid">29220346</pub-id>
</mixed-citation></ref><ref id="ref16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sadeghi</surname><given-names>F</given-names></name><name><surname>Sarkady</surname><given-names>F</given-names></name><name><surname>Zs&#x000f3;ri</surname><given-names>KS</given-names></name><name><surname>Szegedi</surname><given-names>I</given-names></name><name><surname>Orb&#x000e1;n-K&#x000e1;lm&#x000e1;ndi</surname><given-names>R</given-names></name><name><surname>Sz&#x000e9;kely</surname><given-names>EG</given-names></name><etal/></person-group>. <article-title>High neutrophil-lymphocyte ratio and low lymphocyte-monocyte ratio combination after thrombolysis is a potential predictor of poor functional outcome of acute ischemic stroke</article-title>. <source>J Pers Med</source>. (<year>2022</year>) <volume>12</volume>:<fpage>1221</fpage>. doi: <pub-id pub-id-type="doi">10.3390/jpm12081221</pub-id>, PMID: <pub-id pub-id-type="pmid">35893315</pub-id>
</mixed-citation></ref><ref id="ref17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><etal/></person-group>. <article-title>PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews</article-title>. <source>BMJ</source>. (<year>2021</year>) <volume>372</volume>:<fpage>n160</fpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.n160</pub-id>, PMID: <pub-id pub-id-type="pmid">33781993</pub-id>
</mixed-citation></ref><ref id="ref18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stang</surname><given-names>A</given-names></name></person-group>. <article-title>Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses</article-title>. <source>Eur J Epidemiol</source>. (<year>2010</year>) <volume>25</volume>:<fpage>603</fpage>&#x02013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s10654-010-9491-z</pub-id>, PMID: <pub-id pub-id-type="pmid">20652370</pub-id>
</mixed-citation></ref><ref id="ref19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>S</given-names></name><name><surname>Tweedie</surname><given-names>R</given-names></name></person-group>. <article-title>Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title>. <source>Biometrics</source>. (<year>2000</year>) <volume>56</volume>:<fpage>455</fpage>&#x02013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.0006-341X.2000.00455.x</pub-id>, PMID: <pub-id pub-id-type="pmid">10877304</pub-id>
</mixed-citation></ref><ref id="ref20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>TR</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>XF</given-names></name><name><surname>Xia</surname><given-names>YJY</given-names></name><name><surname>Hu</surname><given-names>MY</given-names></name><name><surname>Feng</surname><given-names>QH</given-names></name><etal/></person-group>. <article-title>Correlation of peripheral blood inflammatory indicators to prognosis after intravenous thrombolysis in acute ischemic stroke: a retrospective study</article-title>. <source>Int J Gen Med</source>. (<year>2024</year>) <volume>17</volume>:<fpage>985</fpage>&#x02013;<lpage>96</lpage>. doi: <pub-id pub-id-type="doi">10.2147/IJGM.S456144</pub-id>, PMID: <pub-id pub-id-type="pmid">38505143</pub-id>
</mixed-citation></ref><ref id="ref21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lux</surname><given-names>D</given-names></name><name><surname>Alakbarzade</surname><given-names>V</given-names></name><name><surname>Bridge</surname><given-names>L</given-names></name><name><surname>Clark</surname><given-names>CN</given-names></name><name><surname>Clarke</surname><given-names>B</given-names></name><name><surname>Zhang</surname><given-names>LQ</given-names></name><etal/></person-group>. <article-title>The association of neutrophil-lymphocyte ratio and lymphocyte-monocyte ratio with 3-month clinical outcome after mechanical thrombectomy following stroke</article-title>. <source>J Neuroinflammation</source>. (<year>2020</year>) <volume>17</volume>:<fpage>60</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12974-020-01739-y</pub-id>, PMID: <pub-id pub-id-type="pmid">32070366</pub-id>
</mixed-citation></ref><ref id="ref22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quan</surname><given-names>XQ</given-names></name><name><surname>Wang</surname><given-names>RC</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>CT</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name></person-group>. <article-title>The predictive value of lymphocyte-to-monocyte ratio in the prognosis of acute coronary syndrome patients: a systematic review and meta-analysis</article-title>. <source>BMC Cardiovasc Disord</source>. (<year>2020</year>) <volume>20</volume>:<fpage>338</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12872-020-01614-x</pub-id>, PMID: <pub-id pub-id-type="pmid">32669086</pub-id>
</mixed-citation></ref><ref id="ref23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>P</given-names></name><name><surname>Feng</surname><given-names>W</given-names></name><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name></person-group>. <article-title>Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis</article-title>. <source>Front Immunol</source>. (<year>2023</year>) <volume>14</volume>:<fpage>1321584</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2023.1321584</pub-id>, PMID: <pub-id pub-id-type="pmid">38090560</pub-id>
</mixed-citation></ref><ref id="ref24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Tang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Systemic immune-inflammatory biomarkers (SII, NLR, PLR and LMR) linked to non-alcoholic fatty liver disease risk</article-title>. <source>Front Immunol</source>. (<year>2024</year>) <volume>15</volume>:<fpage>1337241</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2024.1337241</pub-id>, PMID: <pub-id pub-id-type="pmid">38481995</pub-id>
</mixed-citation></ref><ref id="ref25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arefhosseini</surname><given-names>S</given-names></name><name><surname>Aghajani</surname><given-names>T</given-names></name><name><surname>Tutunchi</surname><given-names>H</given-names></name><name><surname>Ebrahimi-Mameghani</surname><given-names>M</given-names></name></person-group>. <article-title>Association of systemic inflammatory indices with anthropometric measures, metabolic factors, and liver function in non-alcoholic fatty liver disease</article-title>. <source>Sci Rep</source>. (<year>2024</year>) <volume>14</volume>:<fpage>12829</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-024-63381-5</pub-id>, PMID: <pub-id pub-id-type="pmid">38834647</pub-id>
</mixed-citation></ref><ref id="ref26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macrez</surname><given-names>R</given-names></name><name><surname>Ali</surname><given-names>C</given-names></name><name><surname>Toutirais</surname><given-names>O</given-names></name><name><surname>Le Mauff</surname><given-names>B</given-names></name><name><surname>Defer</surname><given-names>G</given-names></name><name><surname>Dirnagl</surname><given-names>U</given-names></name><etal/></person-group>. <article-title>Stroke and the immune system: from pathophysiology to new therapeutic strategies</article-title>. <source>Lancet Neurol</source>. (<year>2011</year>) <volume>10</volume>:<fpage>471</fpage>&#x02013;<lpage>80</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1474-4422(11)70066-7</pub-id>, PMID: <pub-id pub-id-type="pmid">21511199</pub-id>
</mixed-citation></ref><ref id="ref27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>G</given-names></name><name><surname>Li</surname><given-names>G</given-names></name></person-group>. <article-title>Inflammatory mechanisms in ischemic stroke: role of inflammatory cells</article-title>. <source>J Leukoc Biol</source>. (<year>2010</year>) <volume>87</volume>:<fpage>779</fpage>&#x02013;<lpage>89</lpage>. doi: <pub-id pub-id-type="doi">10.1189/jlb.1109766</pub-id>, PMID: <pub-id pub-id-type="pmid">20130219</pub-id>
</mixed-citation></ref><ref id="ref28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liberale</surname><given-names>L</given-names></name><name><surname>Montecucco</surname><given-names>F</given-names></name><name><surname>Bonaventura</surname><given-names>A</given-names></name><name><surname>Casetta</surname><given-names>I</given-names></name><name><surname>Seraceni</surname><given-names>S</given-names></name><name><surname>Trentini</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Monocyte count at onset predicts poststroke outcomes during a 90-day follow-up</article-title>. <source>Eur J Clin Investig</source>. (<year>2017</year>) <volume>47</volume>:<fpage>702</fpage>&#x02013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1111/eci.12795</pub-id>, PMID: <pub-id pub-id-type="pmid">28783210</pub-id>
</mixed-citation></ref><ref id="ref29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gittler</surname><given-names>M</given-names></name><name><surname>Davis</surname><given-names>AM</given-names></name></person-group>. <article-title>Guidelines for adult stroke rehabilitation and recovery</article-title>. <source>JAMA</source>. (<year>2018</year>) <volume>319</volume>:<fpage>820</fpage>&#x02013;<lpage>1</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2017.22036</pub-id>, PMID: <pub-id pub-id-type="pmid">29486016</pub-id>
</mixed-citation></ref><ref id="ref30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonz&#x000e1;lez</surname><given-names>A</given-names></name><name><surname>Moniche</surname><given-names>F</given-names></name><name><surname>Cayuela</surname><given-names>A</given-names></name><name><surname>Garc&#x000ed;a-Lozano</surname><given-names>JR</given-names></name><name><surname>Torrecillas</surname><given-names>F</given-names></name><name><surname>Escudero-Mart&#x000ed;nez</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Effect of CYP2C19 polymorphisms on the platelet response to Clopidogrel and influence on the effect of high versus standard dose Clopidogrel in carotid artery stenting</article-title>. <source>Eur J Vasc Endovasc Surg</source>. (<year>2016</year>) <volume>51</volume>:<fpage>175</fpage>&#x02013;<lpage>86</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejvs.2015.09.020</pub-id>, PMID: <pub-id pub-id-type="pmid">26526111</pub-id>
</mixed-citation></ref><ref id="ref31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnston</surname><given-names>SC</given-names></name><name><surname>Easton</surname><given-names>JD</given-names></name><name><surname>Farrant</surname><given-names>M</given-names></name><name><surname>Barsan</surname><given-names>W</given-names></name><name><surname>Conwit</surname><given-names>RA</given-names></name><name><surname>Elm</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA</article-title>. <source>N Engl J Med</source>. (<year>2018</year>) <volume>379</volume>:<fpage>215</fpage>&#x02013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1800410</pub-id>, PMID: <pub-id pub-id-type="pmid">29766750</pub-id>
</mixed-citation></ref><ref id="ref32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishijima</surname><given-names>TF</given-names></name><name><surname>Muss</surname><given-names>HB</given-names></name><name><surname>Shachar</surname><given-names>SS</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Takamatsu</surname><given-names>Y</given-names></name></person-group>. <article-title>Prognostic value of lymphocyte-to-monocyte ratio in patients with solid tumors: a systematic review and meta-analysis</article-title>. <source>Cancer Treat Rev</source>. (<year>2015</year>) <volume>41</volume>:<fpage>971</fpage>&#x02013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ctrv.2015.10.003</pub-id>, PMID: <pub-id pub-id-type="pmid">26481060</pub-id>
</mixed-citation></ref><ref id="ref33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinear</surname><given-names>CM</given-names></name><name><surname>Smith</surname><given-names>MC</given-names></name><name><surname>Byblow</surname><given-names>WD</given-names></name></person-group>. <article-title>Prediction tools for stroke rehabilitation</article-title>. <source>Stroke</source>. (<year>2019</year>) <volume>50</volume>:<fpage>3314</fpage>&#x02013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STROKEAHA.119.025696</pub-id><pub-id pub-id-type="pmid">31610763</pub-id>
</mixed-citation></ref><ref id="ref34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winstein</surname><given-names>CJ</given-names></name><name><surname>Stein</surname><given-names>J</given-names></name><name><surname>Arena</surname><given-names>R</given-names></name><name><surname>Bates</surname><given-names>B</given-names></name><name><surname>Cherney</surname><given-names>LR</given-names></name><name><surname>Cramer</surname><given-names>SC</given-names></name><etal/></person-group>. <article-title>Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. (<year>2016</year>) <volume>47</volume>:<fpage>e98</fpage>&#x02013;<lpage>e169</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STR.0000000000000098</pub-id>, PMID: <pub-id pub-id-type="pmid">27145936</pub-id>
</mixed-citation></ref><ref id="ref35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Powers</surname><given-names>WJ</given-names></name><name><surname>Rabinstein</surname><given-names>AA</given-names></name><name><surname>Ackerson</surname><given-names>T</given-names></name><name><surname>Adeoye</surname><given-names>OM</given-names></name><name><surname>Bambakidis</surname><given-names>NC</given-names></name><name><surname>Becker</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association</article-title>. <source>Stroke</source>. (<year>2019</year>) <volume>50</volume>:<fpage>e344</fpage>&#x02013;<lpage>418</lpage>. doi: <pub-id pub-id-type="doi">10.1161/STR.0000000000000211</pub-id><pub-id pub-id-type="pmid">31662037</pub-id>
</mixed-citation></ref><ref id="ref36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dziedzic</surname><given-names>T</given-names></name></person-group>. <article-title>Systemic inflammation as a therapeutic target in acute ischemic stroke</article-title>. <source>Expert Rev Neurother</source>. (<year>2015</year>) <volume>15</volume>:<fpage>523</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14737175.2015.1035712</pub-id>, PMID: <pub-id pub-id-type="pmid">25865856</pub-id>
</mixed-citation></ref><ref id="ref37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Hansson</surname><given-names>GK</given-names></name></person-group>. <article-title>Inflammation in atherosclerosis: from pathophysiology to practice</article-title>. <source>J Am Coll Cardiol</source>. (<year>2009</year>) <volume>54</volume>:<fpage>2129</fpage>&#x02013;<lpage>38</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jacc.2009.09.009</pub-id>, PMID: <pub-id pub-id-type="pmid">19942084</pub-id>
</mixed-citation></ref><ref id="ref38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quinn</surname><given-names>TJ</given-names></name><name><surname>Dawson</surname><given-names>J</given-names></name><name><surname>Walters</surname><given-names>MR</given-names></name><name><surname>Lees</surname><given-names>KR</given-names></name></person-group>. <article-title>Functional outcome measures in contemporary stroke trials</article-title>. <source>Int J Stroke</source>. (<year>2009</year>) <volume>4</volume>:<fpage>200</fpage>&#x02013;<lpage>5</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1747-4949.2009.00271.x</pub-id>, PMID: <pub-id pub-id-type="pmid">19659822</pub-id>
</mixed-citation></ref><ref id="ref39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>Menon</surname><given-names>BK</given-names></name><name><surname>van Zwam</surname><given-names>WH</given-names></name><name><surname>Dippel</surname><given-names>DW</given-names></name><name><surname>Mitchell</surname><given-names>PJ</given-names></name><name><surname>Demchuk</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials</article-title>. <source>Lancet</source>. (<year>2016</year>) <volume>387</volume>:<fpage>1723</fpage>&#x02013;<lpage>31</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(16)00163-X</pub-id>, PMID: <pub-id pub-id-type="pmid">26898852</pub-id>
</mixed-citation></ref><ref id="ref40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saver</surname><given-names>JL</given-names></name><name><surname>Goyal</surname><given-names>M</given-names></name><name><surname>van der Lugt</surname><given-names>A</given-names></name><name><surname>Menon</surname><given-names>BK</given-names></name><name><surname>Majoie</surname><given-names>CB</given-names></name><name><surname>Dippel</surname><given-names>DW</given-names></name><etal/></person-group>. <article-title>Time to treatment with endovascular Thrombectomy and outcomes from ischemic stroke: a Meta-analysis</article-title>. <source>JAMA</source>. (<year>2016</year>) <volume>316</volume>:<fpage>1279</fpage>&#x02013;<lpage>88</lpage>. doi: <pub-id pub-id-type="doi">10.1001/jama.2016.13647</pub-id>, PMID: <pub-id pub-id-type="pmid">27673305</pub-id>
</mixed-citation></ref></ref-list></back></article>